跳至主要内容
临床试验/NCT01187589
NCT01187589已完成不适用

Preliminary Assessment of the Effect of PulseHaler™ With Albuterol on Lung Deposition of Aerosol and on Pulmonary Functions in COPD Patients

Respinova LTD1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2010年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Respinova LTD
入组人数
15
试验地点
1
主要终点
Lung deposition

研究概览

简要总结

This study is aimed at finding the effect of PulseHaler™ with Albuterol on Lung Deposition of Aerosol and on Pulmonary Functions in COPD Patients

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), established for at least 1 year
  • Post-bronchodilator FEV1/FVC < 0.7
  • Post-bronchodilator FEV1 in the range 30% - 70% predicted
  • Age: 40 years or older
  • Patient signed the informed consent form

排除标准

  • Pneumothorax in the past, per anamnesis.
  • Women at the age of fertility, who are pregnant, or plan pregnancy, or do not use contraceptive.
  • Severe cardiac disease, e.g., Congestive Heart Failure (CHF) grade 3 or higher
  • Coronary Artery Bypass Graft (CABG) or Acute Myocardial Infarction (MI) within last 3 months
  • Other severe systemic disease
  • Non-cooperative or non-compliant patient

研究组 & 干预措施

Pulsehaler

Experimental

Fully operational Pulsehaler, with protocol enabled

干预措施: Pulsehaler (Device)

Pulsehaler

Experimental

Fully operational Pulsehaler, with protocol enabled

干预措施: Nebulizer & Albuterol 0.5ml (Drug)

Nebulizer

Active Comparator

Deactivated Pulsehaler (protocol disabled), so only the nebulizer is active

干预措施: Nebulizer & Albuterol 0.5ml (Drug)

结局指标

主要结局

Lung deposition

时间窗: 1 hour

Lung deposition of the albuterol-containing aerosol

Pulmonary functions

时间窗: 1 hour

Pulmonary function tests by spirometry

次要结局

  • Dyspnea(1 hour)

研究者

发起方
Respinova LTD
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验